A systematic review of patients', parents’ and healthcare professionals’ adrenaline auto-injector administration techniques by El Turki, Aisha et al.
 
 
2 
 
A systematic review of patients', parents' and healthcare professionals' adrenaline auto-1 
injector administration techniques 2 
Aisha El Turki, PhD1, Helen Smith DM1, Carrie Llewellyn PhD1, Christina J Jones PhD1 3 
 4 
1Division of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, 5 
United Kingdom 6 
 7 
Corresponding author:  8 
Dr Christina Jones 9 
Brighton & Sussex Medical 10 
Royal Alexandra Children’s Hospital 11 
Eastern Road 12 
Brighton 13 
BN2 5BE 14 
Telephone number: +44 (0)1273 696955 ext 2540 15 
Fax: +44 (0)1273 523130 16 
Email: C.Jones@bsms.ac.uk  17 
 18 
Key words 19 
Adrenaline; adrenaline auto injectors; administration; anaphylaxis; technique 20 
 21 
Word count: 3194 22 
 23 
  24 
 
 
3 
 
Abstract  25 
Introduction  26 
In order to enable fast treatment response to anaphylactic reactions, adrenaline auto-injectors 27 
(AAI) have been developed and manufactured. It has been reported in several studies that 28 
administration technique is suboptimal. The primary purpose of this study was to review the nature 29 
and extent of the deficiencies in administration technique amongst patients, parents/caregivers and 30 
healthcare professionals.  31 
Methods 32 
Relevant publications were identified between 1998-2015 using two search methods: a keyword 33 
search in Embase, Pubmed, BNI and CINAHL and a search of reference lists of relevant articles. 34 
Results 35 
Twenty three studies met the inclusion criteria. Overall 37% of patients, 32% of parents/caregivers 36 
and 21% of healthcare professionals demonstrated correct administration technique. For studies 37 
which employed a before and after-training study design, correct technique was achieved in 77% 38 
of patients, 79% of caregivers and 65% of healthcare professionals. The most consistently 39 
observed error was the failure to hold the device in place for the recommended time. For patients, 40 
factors associated with good technique were being aged over 18, trained in AAI administration by 41 
an allergist, prescribed an AAI for more than 30 months, having a history of severe anaphylaxis 42 
and membership of a support group. For parents/caregivers in addition to those mentioned, being 43 
given a training device with which to practice, improved technique.  44 
Discussion 45 
There was wide variation in administration techniques reported. However, studies designed using 46 
before and after-training show that even a brief demonstration and educational intervention can 47 
improve technique. Further studies are required to design and pilot acceptable and cost-effective 48 
educational materials.  49 
 50 
 51 
 52 
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What this paper adds? 53 
 Numerous observational studies and anecdotal evidence have suggested that patients and 54 
health professionals use of adrenaline auto-injectors (AAIs) is suboptimal 55 
 This review identifies which steps to administration are contributing to this failure and what 56 
factors are linked to success 57 
 This review highlights the step to administration most frequently failed (holding the device in 58 
place for the recommended time) 59 
 Additionally, this review identifies successful interventions and patient-factors (e.g. severity 60 
of allergy, age of AAI-owner) which are shown to improve administration  61 
 The identification of these successful approaches are timely as the European Medicines 62 
Agency have released a call for better training tools recommended to support patients who 63 
use AAIs 64 
 65 
 66 
Abbreviations 67 
AAI     Adrenaline auto injector 68 
EAACI    European Academy of Allergy & Clinical Immunology 69 
HCPs    Health Care Professionals 70 
PRISMA   Preferred Reporting Items for Systematic Review and Meta-Analyses 71 
MMAT    Mixed Method Appraisal Tool 72 
EMA    European Medicines Agency    73 
    74 
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Introduction 75 
Adrenaline auto-injectors (AAIs) are first line treatment for anaphylaxis in the community. Prompt 76 
injection with adrenaline can be life-saving and abort the progression of the anaphylactic reaction, 77 
allowing time to seek formal medical assessment and management. The European Academy of 78 
Allergy and Clinical Immunology (EAACI) describes six absolute indications for the prescription of 79 
an AAI including food and latex anaphylaxis, exercise-induced anaphylaxis, idiopathic anaphylaxis, 80 
moderate to severe persistent asthma with food allergy, venom allergy or underlying mast cell 81 
disorder (1). Unlike other allergic conditions, such as rhinitis and eczema, whose prevalence 82 
appears to be stabilising over the last decade, anaphylaxis appears to be increasing (2). Rates of 83 
hospital admissions in the UK for all causes of anaphylaxis increased seven-fold between 1992-84 
2012 whilst prescriptions for AAIs increased four-fold from 1998-2012 (3). Anaphylaxis is the cause 85 
of approximately 20 deaths each year in the UK (4). 86 
 87 
AAI is the main emergency treatment for individuals experiencing anaphylaxis, but its effectiveness 88 
is largely reliant on correct administration. Over the last few years, studies have assessed 89 
healthcare professionals’, patients’ and parents’ administration techniques and skills with respect 90 
to the emergency management of anaphylaxis. The primary purpose of this review was to assess 91 
the magnitude of the deficit in administration technique and to summarise which stages in the 92 
process of administering AAIs are most problematic. Reviewing data from a broad number of 93 
studies will help inform the development of AAI design and educational interventions for improving 94 
future utilisation.  95 
  96 
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Methods 97 
Search strategy 98 
A systematic review of literature published between January 1998 to August 2015 was undertaken 99 
using four databases (Embase, Pubmed, BNI and CINAHL) (see online supplementary appendix 100 
1). Subsequently a search of the reference lists from relevant papers was performed. No language 101 
restrictions were applied.   102 
 103 
Inclusion and exclusion criteria 104 
This review focused on studies that included an assessment of AAI technique (either by 105 
demonstration or questionnaire) in three populations: patients (paediatric and adult), 106 
parents/caregivers of children diagnosed with anaphylaxis and prescribed an AAI device and 107 
health care professionals (HCPs). Studies were eligible if they were quantitative in nature including 108 
cross-sectional/observational studies, before-and-after studies or randomised controlled trials.  109 
 110 
Study selection  111 
Two reviewers (CJ and AT) independently reviewed the titles and then abstracts of articles 112 
generated by the electronic bibliographic search, rejecting any articles that clearly did not meet 113 
eligibility criteria. There was no disagreement between reviewer’s regarding the eligibility of the 114 
studies although both reviewers were unsure of inclusion of three studies. These were discussed 115 
with a third author (HS) and a consensus reached. The Preferred Reporting Items for Systematic 116 
Review and Meta-Analyses (PRISMA) (5) flow diagram was used to summarise the systematic 117 
review process (Figure 1). Authors of relevant published conference abstracts were contacted to 118 
determine if full study details were available.   119 
 120 
Data extraction 121 
The process of AAI administration is frequently described by manufacturers and researchers as six 122 
component steps (device recognition, removal of safety cap, selection of appropriate injection site, 123 
application of correct end of device to body, administration of adrenaline and retaining AAI in 124 
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place). We adopted these commonly used steps to prepare a standardised data extraction form 125 
and extracted data from the papers on participants’ ability relating to each of these steps (Tables 1-126 
3). One reviewer (AeT) extracted the data with a second (CJ) cross-checking 50% to ensure 127 
accuracy which was high. In addition we noted any additional skills or knowledge assessed, (i.e. 128 
checking expiry date of the AAI), and any factors which were associated with correct administration 129 
technique. 130 
 131 
Assessment of study quality  132 
All studies included in the systematic review were evaluated for quality using the mixed methods 133 
appraisal tool (MMAT) (6). The MMAT has proven to be an effective and practical quality 134 
assessment tool for systematic reviews which include different study designs or mixed methods 135 
(7). The tool consists of two screening questions followed by four criteria for the appraisal of study 136 
quality according to study design. The MMAT enabled all studies included in this review to be 137 
assessed within each of the methodological domains used. The MMAT scores range from to 0% 138 
(no criterion is met) to 100% (all four criteria are met). Studies were assessed by one reviewer 139 
experienced in conducting quality assessments (CJ). 25% of the studies were checked by a 140 
second reviewer with any disagreement being resolved by discussion until consensus was 141 
reached. 142 
 143 
Results 144 
 145 
From 1434 studies a total of 23 studies met the inclusion criteria (Figure 1). Eight studies came 146 
from the UK (8-15), six from North America (16-21), four from Turkey (22-25), three from Australia 147 
(26-28), and two from Israel (29,30) (Tables 1, 2 & 3).  Sixteen studies were cross-sectional  five 148 
were before and after studies, one was a longitudinal survey and one was a randomised controlled 149 
trial. Nineteen papers requested participants to demonstrate use of the AAI. Four studies used a 150 
questionnaire technique in which the participants responded to true/false questions or described 151 
their technique. The papers varied in their focus, four assessed the techniques and skills of 152 
patients only, eight focussed on parents/caregivers only and six papers on HCPs only.  Five 153 
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studies had broader focus; four of which included patients and parents/caregivers, and one study 154 
included patients, parents/caregivers and HCPs. The findings of the studies are presented to 155 
reflect the three populations of interest; patients (9 studies), parents/caregivers (13 studies), and 156 
HCPs (7 studies), with studies reporting multiple populations presented in each of the relevant 157 
tables (Tables 1-3). The studies which employed a before and after design or RCT of the effect of 158 
instruction on AAI technique were isolated in order to clearly reflect on these findings (Table 4). 159 
 160 
Patients  161 
We identified nine studies (550 participants) which documented patient AAI administration 162 
technique; all were based in allergy clinic settings (Table 1). Administration assessments varied 163 
from five to nine steps. Overall, prior to receiving any instruction or demonstration as part of the 164 
study, 37% of patients were able to demonstrate or detail correct administration technique (range 165 
6-74%). This rose to 77% overall for two studies which reported a before and after instruction 166 
design (Table 4). The most consistently reported error was the failure to hold the AAI in place for 167 
10 seconds (step 6 Table 1), followed by a failure to apply enough pressure to activate (step 5 168 
Table 1). Six studies reported whether patients had received previous training on how to use AAI, 169 
on average 71% patients reported either visual instruction using a trainer device or verbal 170 
instruction (range 11-100%). Five studies identified five patient-related factors associated with 171 
good AAI technique: being aged over 18, being trained by an allergy specialist, having an AAI for 172 
more than 2½ years, membership of a support group and having a history of severe anaphylaxis.  173 
 174 
Parent/caregivers 175 
We identified 13 studies documenting parental/caregiver AAI administration technique, ten of which 176 
reported the number of parents/caregivers participating (1182 participants). Eleven studies were 177 
based in allergy clinics, one study recruited participants from local schools and another from 178 
support groups and a private allergy clinic. Out of the 5 studies which reported findings for both 179 
patients/caregivers and patients, three did not provide separate results for parents/caregivers and 180 
patients and report patients and parents/caregivers results together. Overall, prior to receiving any 181 
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instruction or demonstration, 32% of parents/caregivers were able to demonstrate or detail correct 182 
administration technique (range 6-57%). This average rose to 79% in the five studies which 183 
reported a randomised trial or before and after instruction design in parents/caregivers (Table 4).  184 
 185 
Amongst parents or caregivers, the most common errors were the same as those reported for 186 
patients; a failure to hold the AAI in place for 10 seconds (step 6), followed by a failure to apply 187 
enough pressure to activate (step 5) (Table 2). Nine studies reported whether parents or 188 
caregivers had received training or demonstration on how to use AAI, on average 70% said they 189 
had received some form of training (range 11-100%). Seven studies reported eight 190 
parental/caregiver related factors which were associated with proper AAI administration technique 191 
which were having a child with: more serious reactions, an AAI for more than 2½ years, 192 
membership to a support group, an AAI prescribed from secondary care, an AAI prescribed by an 193 
allergy specialist, insect sting allergy, a training device with a Auvi-Q (audio-prompt) device. 194 
 195 
Health care professionals (HCPs) 196 
We identified seven studies which documented HCPs AAI administration technique (923 197 
participants); two were based in primary care, two in paediatric departments and one each in an 198 
allergy clinic, community pharmacy and a medical conference (Table 3). Overall, 21% of HCPs 199 
were able to demonstrate proper AAI technique prior to receiving any demonstration or instruction. 200 
One study reported a before and after instruction study design and showed an increase from 18% 201 
to 65% in proper AAI technique amongst community pharmacists (Table 4). The most commonly 202 
reported error was the failure to hold the AAI in place for at least 10 seconds (step 6) (Table 3). 203 
Accidental digital injection would have occurred in 21% of participants. One study reported the risk 204 
of accidental digital injection reduced from 36% to 7% post-education. Three studies reviewed how 205 
many HCPs provided training on AAI technique to their patients, which was 28% overall (range 19-206 
51%). In the two studies which looked at factors associated with proper AAI administration 207 
technique amongst HCPs, two factors were identified: being a pharmacist and having a more 208 
general awareness of anaphylaxis management (specifically asking patients about a management 209 
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plan, advising patients to call an ambulance after administration and explaining the side effects of 210 
adrenaline). 211 
 212 
Quality assessment 213 
Of the 23 studies included in this systematic review, no studies scored 100%, five studies scored 214 
75% (three criteria met), nine scored 50% (two crirteria met), seven scored 25% (one criterion met) 215 
and 2 studies scored 0 (Tables 1-3, online supplementary online appendix 2). Shortcomings in 216 
study quality were often found in the description of the sampling strategy used and the failure to 217 
include a sample size calculation. It was also difficult to ascertain the response rate of studies and 218 
any differences between responders and non-responders. Patients were often inadequately 219 
described and it was not always clear who the respondents were. Although most studies 220 
adequately reported how AAI administration was assessed, this varied significantly between 221 
studies.  222 
 223 
Discussion  224 
Administration technique and skills in using AAI have been documented to be consistently deficient 225 
over the last 17 years across six different countries. Correct administration technique varied widely 226 
but overall was 30% for patients, 32% for parents/caregivers and 21% for HCPs. For studies which 227 
employed a before and after design of the impact of training, correct technique was achieved in 228 
77% in patients, 79% in caregivers and 65% in HCPs. Approximately 70% of patients and 229 
parents/caregivers reported receiving some form of AAI training yet only 28% of HCPs reported 230 
providing training. The most consistently observed error common to all three populations was the 231 
failure to hold the device in place for the recommended time, and additionally for patients and 232 
parents/caregivers, the failure to apply enough pressure to activate.  233 
 234 
In addition to observing correct administration technique, 14 studies reported factors related to 235 
proper administration technique. For patients, being aged over 18, trained in AAI use by an 236 
allergist, prescription of an AAI for more than 30 months, history of severe anaphylaxis and 237 
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membership of a support group, were all related to better technique. In addition to those already 238 
mentioned, for parents/caregivers, having a training device with which to practice and using an 239 
Auvi-Q instead of an EpiPen or Anapen were also correlated with better administration technique. 240 
Pharmacists and other HCPs who had a greater general awareness of managing anaphylaxis also 241 
demonstrated better administration technique.   242 
 243 
This is the first systematic review to explicitly detail the deficiencies in HCPs’, patients’ and 244 
parent/caregivers’ AAI administration technique. This review also identified seven studies which 245 
used a study design to improve administration technique. Several educational approaches to 246 
improving technique were reported varying from a simple two minute demonstration of 247 
administration using a training device to a multidisciplinary approach involving an individualised 248 
anaphylaxis management plan, followed by education from a clinical nurse specialist and a dietetic 249 
assessment to provide families with advice on food avoidance. The time between training and 250 
assessment varied from immediate to approximately one year indicating that some of the training 251 
techniques were effective at improving administration over a long term period. The identification of 252 
these successful approaches are timely as the European Medicines Agency have released a call 253 
for better training tools recommended to support patients who use AAIs (31).  254 
 255 
There are some limitations to the conclusions drawn from this review. Results in three studies were 256 
not separated to reflect administration techniques of the patients and parents/caregivers giving a 257 
total score for both which could suggest why overall scores and most common errors were 258 
mirrored between these groups. Additionally, the estimates of correct administration technique may 259 
be optimistic for three reasons. Firstly, the majority of participants in these studies were self-260 
selected with often no description of differences between responders and non-responders, and 261 
may reflect responder bias. However, we know from a recent study involving mothers of non-262 
allergic children with no previous experience of AAIs that only 15% were able to administer the 263 
device (32), a figure which falls in the range of correct administration scores by experienced 264 
parents/caregivers found in this systematic review (6-57%). Secondly, although the majority of 265 
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studies used demonstration to assess administration (82%), self-reported questionnaires were 266 
used in the remaining studies indicating that findings may not reflect actual behaviour. Thirdly, it is 267 
difficult to capture how the high pressure situation of a “real-life” anaphylaxis emergency would 268 
impact AAI administration technique compared to the more controlled scenarios proposed in the 269 
research setting.  270 
 271 
In relation to the scores used to determine correct technique in studies, these varied from zero to 272 
nine steps with some items not directly related or not critical to administration (i.e. awareness of an 273 
expiry date) which may underrepresent ability to administer device. The studies included in this 274 
systematic review related predominantly, but not exclusively, to one particular device (EpiPen). 275 
The introduction of newer AAIs such as the next generation EpiPen, Jext, Emerade and Auvi-Q 276 
may impact on future assessments, although the majority of these devices use the same/similar 277 
injecting mechanisms. The most recent study in this review compared AAI use between devices 278 
and found that when prescribed a new device without receiving specific training, successful 279 
administration rates for mothers were higher with Auvi-Q (an audio-prompt AAI) (93%) than other 280 
traditional devices (i.e. EpiPen, Anapen, Jext) (49%) (15). It is likely that correct administration 281 
rates will increase if audio-prompt devices are made readily available. However, the steps 282 
identified as being most likely to be performed incorrectly (e.g. holding the device for the 283 
recommended time and applying enough pressure to activate), are common to all AAIs and 284 
emphasising the importance of this to patients, parents/caregivers and HCPs during training is 285 
essential. Some may argue that the interval between triggering the device and removal of the 286 
needle need not be 10 seconds as research has found that for the EpiPen, delivery time is 0.3 287 
seconds (33). However, there are no disadvantages to holding the device in place for a longer 288 
period as this discourages rapid removal and is consistent with the majority of manufacturer 289 
guidelines (Epi-Pen, Jext, Anapen), although the more recently introduced Auvi-Q recommends 5 290 
seconds. Related to training, we observed a 2.5 fold increase in correct administration technique 291 
for patients and parents/caregivers and 3-fold increase in HCPs emphasizing the beneficial effect 292 
training can have on technique.  293 
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 294 
Two non-systematic short-cut reviews conducted in 2013 to determine knowledge of correct AAI 295 
use in parents of allergic children and doctors (34,35) failed to identify five key studies. Our more 296 
recent, robust and extensive systematic review involving four databases, including papers 297 
published in any language identified these five studies plus two more recently published studies. 298 
We also present evidence on the most commonly reported mistakes in administration technique, 299 
important for the design of future studies which need to move away from documenting poor 300 
technique and towards interventions to improve administration technique. Furthermore, our 301 
systematic review differentiates between patients, parents/caregivers and HCPs’ correct use of 302 
auto-injectors and identifies factors related to successful administration technique.     303 
 304 
Clinical implications 305 
The lack of correct administration technique among patients and parent/caregivers is worrying, but 306 
of greater concern is the variation in techniques observed amongst HCPs. Familiarity with 307 
epinephrine as the first-line response in the treatment of anaphylaxis was widespread but fewer 308 
were able to detail correct auto-injector technique, suggesting that if prescribing AAI, HCPs could 309 
be misinforming or not informing patients how to use the device correctly. The latter is likely given 310 
the observation that the majority (70%) of patients and parent/caregivers received training on how 311 
to use the device yet only 28% of HCPs included in this review reported providing training. It may 312 
be useful to identify those who provide training (if not the HCPs in this review), to ensure that their 313 
methods, knowledge and resources are up-to-date. Also, only five studies looked at recognition of 314 
symptoms of anaphylaxis or indications for using AAI with wide variation in those which reported 315 
results. Indications for AAI use is important to address during patient consultation to avoid either 316 
inappropriate use and consequent emergency admissions or more importantly, fatalities from the 317 
delayed administration of AAI (36). 318 
 319 
Indicators of poor technique and ability were found amongst those patients who were instructed on 320 
the use of device or cared for by general practitioners or non-allergy specialists compared to those 321 
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cared for by allergy specialists. Those cared for by an allergy specialist were more confident and 322 
more likely to carry and have the ability to activate the device. Other significant associations were 323 
found. For instance, several studies reported significant positive effects on technique and 324 
performance if the patient was a member of an allergy support group. Further work is underway to 325 
determine which aspects of support groups are important to patients in terms of knowing how and 326 
when to use their AAI but highlights the importance of recommending patients to join support 327 
groups. There was no effect on performance in relation to the time interval since training was 328 
received. Specifically, two studies showed that correct technique was no more likely to be 329 
demonstrated if training had been received in the last six months or over 24 months. This 330 
demonstrates the necessity for thorough training in the use of the device at initial consultation. 331 
 332 
Future Studies  333 
With this plethora of studies documenting poor administration technique it is time to concentrate on 334 
identifying and designing interventions targeting theses areas of poor technique highlighted. 335 
Patients and parents/caregivers should be involved in the design of training resources to ensure 336 
they are acceptable and understandable in order to address their learning needs. Amongst HCPs, 337 
training regarding the use of the device and how to communicate this effectively to patients should 338 
be addressed as well as ensuring training devices are available to supply to their patients. 339 
Successful educational materials and tools have been identified but further studies should be 340 
conducted to determine the cost-effectiveness of these approaches. Further research is required to 341 
address other important issues such, poor retention of information (by HCPs and 342 
patients/caregivers) after training, the frequency of re-training needed, and how to balance time 343 
needed to train versus HCPs' other time constraints.  344 
 345 
  346 
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 485 
Figure1: PRISMA flow diagram for the identification of studies 486 
assessing healthcare professionals and patients’ administration 487 
techniques of adrenaline auto-injectors 488 
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Table 1. Adolescent and adult patients’ technique and skills administering an adrenaline auto-injector (Studies are presented in chronological order)    
Studies (country, 
design, method of 
observation, 
quality 
assessment) 
Study 
population 
% individuals correctly undertaking key steps of AAI administration 
 (wording used) 
100% correct Additional observations 
  Device 
Recognition 
Removal of 
safety cap 
Selection of 
appropriate 
injection site 
Application of 
correct end of 
AAI to thigh 
Administration 
of adrenaline 
Holding AAI in 
place  
  
Huang, 1998 
USA 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
98 patients  
(83 aged <18y, 15 
aged ≥18y)   
For <12ys, parents 
were assessed 
(exact number 
not provided) 
Not assessed 
 
90% 
 
(“Remove the 
cap”) 
 
78% 
 
(“Press the Epi-
PEN on the 
lateral thigh”) 
Not assessed 37% 
 
(“Press Epi-PEN 
until clicking 
sound is heard”) 
 
41% 
 
(“Hold Epi-PEN in 
place for at least 
10 seconds”) 
 
Not reported 16% knew the circumstances in 
which the use of AAI is indicated 
 
84% had two devices available 
 
53% knew to use through 
clothing 
 
97% aware of expiry date but 
89% had a valid device with them 
 
11% had previously been trained 
in how to use AAI (5% by an 
allergist and 6% by other 
physician) 
Goldberg and 
Confino-Cohen, 2000          
Israel 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
75% 
96 patients (n=72 
aged <12y) 
Children aged 
≥12y were 
assisted in 
answering 
questions by 
parents  and 
results indicate 
parental response 
(n=24)                                              
Not assessed  82% 
 
(“Pulling out the 
grey safety tip”) 
 
82% 
 
(“Holding the 
device in palm”) 
 
 
 
 
82% 
 
(“placing the 
black tip on the 
outer thigh”) 
 
76% 
 
(“Pushing in hard 
until the trainer 
function is 
heard”) 
 
78% 
 
(“Holding it in 
place for 10 
seconds”) 
 
36% patients ≥12 y 
 
 
89% had previously been trained 
in how to use AAI (46% by an 
allergist, 12% by a nurse, 10% by 
a primary physician, 10% by a 
pharmacist, 1% by emergency 
department physician and 9% by 
a non-professional) 
 
Mean time since last training 
received was 2.6 years 
 
18% received instruction with 
training device  
 
Proper injection technique was 
more common among patients 
>18years who were trained by an 
allergist 
Sicherer et al., 2000 
USA 
 
Cross-sectional  
101 families of 
newly referred 
food allergic 
children (95 
68% approx.* 
 
(“Familiar with 
device” 
55% approx.*  
 
(“Removes cap”) 
 
93% approx.* 
 
(“Selects correct 
end”)  
93% approx.* 
 
(“Selects correct 
injection site”) 
59% approx.* 
 
(“Presses to 
activate”) 
53% approx.* 
 
38% Patient/ 
Parents 
 
  
* Approximate values extracted 
from graphs in published paper 
 
  
  
 
 
Assessment by 
demonstration 
 
50% 
parents and 6 
children >12y) & 
36 physicians 
   (“Holds in place 
several 
seconds”)  
The data presented in this 
publication combined findings for 
patients and parents. No 
separate results provided for 
patients; results combined for 
patients and parents 
 
55% patients had non-expired 
AAI with them 
 
49% reported previous 
demonstration of the device by a 
physician and 80% stated that 
use was explained verbally 
 
98% said they would seek 
medical advice after 
administration  
 
Correct use was associated with 
having had the device >2.5years 
and membership of a support 
group 
Al-Matar and 
Sussman, 2001 
Canada 
 
Before and after 
study with two 
minute instruction 
before immediate re-
assessment 
 
Assessment by 
demonstration 
 
25% 
55 patients aged 
4-67y (mean age 
34y) (unclear if 
younger aged 
participants were 
assessed directly 
or responses 
referred to 
parents) 
Not assessed 64% 
 
(“Take the cap 
off”) 
 
64% 
 
(“Injection site”) 
 
64% 
 
(“Injecting with 
the wrong end” 
or “not holding 
the device at the 
injector end”)  
 
Not reported 
 
(“Pressing hard 
enough”) 
 
Not assessed Pre-instruction 13%  
 
Post-instruction 
100% 
Technical errors included failure 
to activate AAI due to not taking 
cap off, not injecting hard 
enough,  injecting with the wrong 
end or not holding the device 
correctly 
Sabroe et al., 2002 
UK 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
0% 
29 patients 
(13y-67y) 
Only 25 patients 
completed 
demonstration 
Not assessed 79% 
 
(“Removed the 
cap”) 
88% 
 
(“Inject into the 
lateral aspect of 
the thigh”) 
Not reported 72%  
 
(“Press until 
hearing a click”) 
 
68%  
 
(“Wait for 10s”) 
 
56% (n=14/25) 
patients were able 
to complete all 
steps 
12% were unable to perform any 
step 
 
56% knew to inject through 
clothing 
 
66% prescribed ≥2 devices 
 
  
  
 
73% replaced AAI according to 
expiry date and of these, 53% 
knew the expiry date 
 
93% trained in how to use device 
(70% by hospital staff, 30% by a 
general practitioner and 7% by a 
pharmacist) 
Diwakar et al., 2010 
UK 
 
Cross-sectional 
 
Assessment by 
questionnaire 
 
25% 
80 patients (mean 
age 37y (SD 15y) 
Not assessed Not assessed % not reported 
 
(“draw out area 
where AAI 
should be 
injected (figure 
provided)”) 
Not assessed Not assessed % not reported 
 
(“How long 
should AAI be 
held against your 
skin after 
injecting?”) 
Not reported 
 
 
Other technique items included 
knowing AAI can be used through 
clothing, what to do after 
injecting AAI and symptoms 
which would precede use (max 
score 7)  
 
73% previously trained in how to 
use device (41% by a specliast, 
32% by non-specialist) 
 
All untrained participants issued 
AAI by non-specialist  
 
Those trained in AAI use by 
specialist  had better AAI 
administration technique than 
those untrained (mean=5.86 
SD=.83 versus mean=5.05, 
SD=1.57) 
 
No difference between those 
trained by specialist or non-
specialist (mean=5.75, SD=.94) 
Segal et al., 2012 
Israel 
 
Before and after 
study with average 12 
months between 
instruction and re-
assessment  
 
Assessment by 
demonstration 
 
50% 
141  (129 parents 
of patients aged 
≤12y and 12 
patients age >12y 
(total age range 
22m-23.4y) 
Not assessed  
 
 
Pre-instruction 
52% 
 
(“Removing the 
cap”) 
 
Pre-instruction 
32% 
 
(“Holding the 
device in first”) 
 
 
Pre-instruction 
34% 
 
(“Placing against 
upper outer 
thigh and 
pressing”) 
 
See previous 
step 
 
 
Pre-instruction 
26% 
 
(“Holding in 
place for 10 
seconds”)  
 
6% were able to 
complete all steps 
at baseline (n=141) 
 
≤19% were able to 
complete all steps 
at first follow up 
(n=41) 
 
≤53% were able to 
completed all steps 
at second follow up 
(n=41) 
77% able to cite at least 2 
symptoms of systemic allergic 
reaction 
 
79% had a valid device 
 
100% trained in how to use 
device 
 
No significant difference 
between patients and parents 
demonstration technique 
Topal et al., 2013 
Turkey 
64 (50 caregivers 
of patients and 14 
74% approx.* 
 
87% approx.* 
 
100% 
 
100% 
 
92% approx.* 
 
36% approx. * 
 
36%  
 
84% knew how to check the 
expiry date 
  
  
 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
patients aged 
≥12y) 
(“Recognise the 
auto injector”) 
(“Remove the 
grey safety cap”) 
(“Selecting the 
outer thigh”) 
(“Applying the 
black end to the 
thigh”) 
(“Pressing it until 
it clicks”) 
(“Holding it in 
place for at least 
10 s”) 
  
*Approximate values derived 
from figure  
 
History of severe anaphylaxis was 
associated with correct use of 
AAI administration (OR:28.3, 95% 
CI:2.50-321.38) 
 
No difference between parent 
and child competence in 
administering device 
Jones et al., 2015 
UK 
 
Cross-sectional  
 
Assessment by 
questionnaire 
 
50% 
188 patients (age 
13-19y) 
Not assessed 80%  
 
(“Need to 
remove AAI cap 
before use”) 
 
99%  
 
(“Selection of 
appropriate 
injection site”) 
 
100% 
 
(“Identifies 
needle end of 
device”)  
Not assessed 86% 
 
(“Length of time 
to keep needle in 
muscle”) 
    
74% 
 
18% *if additional 
technique items 
included 
98% recognised symptoms of 
anaphylaxis 
 
 56% knew the correct grip 
(thumb clear of end of the 
device) 
 
68% knew to seek medical advice 
following administration 
 
98%  aware that the device has 
expiry date 
 
93% aware of using the injection 
through clothing 
 
*low % correct reported in paper 
as the above additional 
technique items were included in 
the total technique score 
 
  
  
  
 
Table 2. Parents’ and carer givers’ technique and skills administering an adrenaline auto-injector (Studies are presented in chronological order)    
Studies (country, 
design, method of 
observation, 
quality 
assessment) 
Study 
population 
% individuals correctly undertaking key steps of AAI administration 
 (wording used) 
100% correct Additional observations 
  Device 
Recognition 
Removal of 
safety cap 
Selection of 
appropriate 
injection site 
Application of 
correct end of 
AAI to thigh 
Administration 
of adrenaline 
Holding AAI in 
place  
  
Huang, 1998 
USA 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
98 patients  
(83 aged <18y, 15 
aged ≥18y)   
For <12ys, 
parents were 
assessed (exact 
number not 
provided) 
Not assessed 
 
90% 
 
(“Remove the 
cap”) 
 
78% 
 
(“Press the Epi-
PEN on the 
lateral thigh”) 
Not assessed 37% 
 
(“Press Epi-PEN 
until clicking 
sound is heard”) 
 
41% 
 
(“Hold Epi-PEN in 
place for at least 
10 seconds”) 
 
Not reported  16% knew the circumstances in 
which the use of AAI is indicated 
 
84% had two devices available 
 
53% knew to use through 
clothing 
 
97% aware of expiry date but 
89% had a valid device with them 
 
11% had previously been trained 
in how to use AAI (5% by an 
allergist and 6% by other 
physician) 
Gold and Sainsbury,  
2000 
Australia 
 
Cross sectional 
 
Assessment by 
questionnaire 
 
75% 
68 parents of 
children with AAI 
(age 1.5-19y) 
 
 
 
Not reported 50% 
 
(“Removal  of 
the grey cap”) 
 
>80% 
 
(“Could describe 
the site of 
administration 
and apply 
pressure”)  
 
Not reported 
 
(“Placing the 
black end on 
thigh”) 
 
Not reported 
 
(“Applying 
pressure until a 
click was heard”) 
50% 
 
(“holding the 
auto-injector in 
place for 10 
seconds”) 
24% parents of 
patients 
 
 
5% could not recall any steps for 
correct use 
 
97% had informed school staff 
about their child’s anaphylaxis 
 
71% did not use their AAI to treat 
anaphylaxis despite it being 
available and in date for 69%  
 
Greater AAI administration  
technique was associated with 
parents whose children had 
experienced more allergic 
reactions 
Goldberg and 
Confino-Cohen, 2000          
Israel 
 
Cross-sectional  
96 patients (n=72 
aged <12y) 
Children aged 
≥12y were helped 
to answer 
Not assessed  82% 
 
(“Pulling out the 
grey safety tip”) 
 
82% 
 
(“Holding the 
device in palm”) 
 
82% 
 
(“placing the 
black tip on the 
outer thigh”) 
76% 
 
(“Pushing in hard 
until the trainer 
78% 
 
(“Holding it in 
place for 10 
seconds”) 
42%  parents of 
patients <12y   
89% had previously been trained 
in how to use AAI (46% by an 
allergist, 12% by a nurse, 10% by 
a primary physician, 10% by a 
pharmacist, 1% by emergency 
  
  
 
 
Assessment by 
demonstration 
 
75% 
questions by their 
parents.  These  
results indicate 
parental 
response (n=24)                                              
 
 
 
 function is 
heard”) 
 
 department physician and 9% by 
a non-professional) 
 
Mean time since last training 
received was 2.6 years 
 
18% received instruction with 
training device  
Sicherer et al., 2000 
USA 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
101 families of 
newly referred 
food allergic 
children (95 
parents and 6 
children, mean 
age 6.4y) & 36 
physicians 
68% approx.* 
 
(“Familiar with 
device” 
55% approx.*  
 
(“Removes cap”) 
 
  
93% approx.* 
 
(“Selects correct 
end”)  
93% approx.* 
 
(“Selects correct 
injection site”) 
59% approx.* 
 
(“Presses to 
activate”) 
 
53% approx.* 
 
(“Holds in place 
several 
seconds”)  
38% Patient/ 
Parents 
 
  
* Approximate values extracted 
from graphs in published paper 
 
The data presented in this 
publication combined findings for 
patients and parents. No 
separate results provided for 
patients; results combined for 
patients and parents 
 
55% patients had non-expired 
AAI with them 
 
49% reported previous 
demonstration of the device by a 
physician and 80% stated that 
use was explained verbally 
 
98% said they would seek 
medical advice after 
administration  
 
Correct use was associated with 
having had the device >2.5years 
and membership of a support 
group  
Blyth and Sundrum, 
2002 
UK 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
0% 
25 parents of 
children with AAI 
(aged 4-17y) 
Not reported 64% 
 
(“Removing the 
cap”) 
Not reported Not reported 60% 
 
(“Pressing on the 
tip to inject 
whilst holding 
the auto-injector 
against the 
thigh”) 
Not reported 24% parents were 
able to complete all 
6 steps 
Three children had been 
prescribed an incorrect dose 
 
64% would call ambulance after 
administration 
 
72% trained in how to use device 
 
Kapoor et al., 2004 
UK 
 
62 parents of 
children with AAI 
(<17 y) 
Not assessed % not reported 
 
% not reported 
 
Not assessed  % not reported 
 
Not assessed Pre-education 50% 
parents able to 
identify all three 
61% previously trained in how to 
use device  
 
  
  
 
Before-after  
 
Assessment by 
demonstration 
 
75% 
 (“Removal of the 
grey safety cap”) 
 
(“Selecting the 
appropriate 
site”) 
 
(“Pressing the 
EpiPen down 
until it click”) 
 
critical steps (steps, 
2, 3 and 5) 
 
Post education 96% 
parents able to 
identify all three 
critical steps 
 
 
Participants referred from 
secondary care had  better 
technique  than those from 
primary care (38% vs 15% correct 
AAI technique at baseline) 
Kim et al., 2005 
USA 
 
Cross sectional 
 
Assessment by 
questionnaire 
 
75% 
165 parents of 
children with AAI 
(aged 1-19y) 
  Not assessed  95% 
 
(“Remove grey 
cap before 
administration”) 
 
92% 
 
(“Inject in 
outside part of 
thigh”) 
Not assessed 79% 
 
(“Press until 
clicking sound 
heard”) 
70% 
 
(“Hold for 10 
seconds after 
injection”) 
  
Not reported 
 
 
93% knew not to remove clothing 
before injecting  
 
77% knew to call 911 oand 65% 
knew to go the emergency 
department following 
administration  
 
88% knew to replace if the liquid 
appeared brown 
 
83% trained in how to use device 
(47% trained by a physician, 36% 
by a nurse) 
Arkwright and 
Farragher, 2006 
UK 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
122 parents of 
children (aged 6-
13y) 
Not assessed % not reported 
 
(“Removed the  
safety cap”) 
% not reported 
 
(“correct site to 
inject 
adrenaline”) 
Not assessed % not reported 
 
(“Applied 
enough pressure 
to trigger the 
device”) 
% not reported 
 
(“Did not take 
the needle out of 
the skin 
immediately 
after the device 
had been 
triggered”) 
57% able to trigger 
device 
 
 
 2 cases with expired date device 
 
81% trained in how to use device 
 
Parents given AAIs by allergy 
specialist were more able to 
trigger the device, carried the 
device, had the correct dose and 
knew when to use the device 
than those given AAIs by GPs or 
non-allergy specialists 
Huang, 2007 
UK 
 
Longitudinal survey 
after auto-injector 
demonstration 
(assessment at 3 
month intervals)  
 
Assessment by 
demonstration 
 
50% 
224 parents of 
children with AAI 
(ages unknown) 
Not assessed % not reported 
 
(“Remove the 
cap”) 
% not reported 
 
(“Choose the 
injection site”) 
% not reported 
  
(“Know the 
orientation of 
the head and tail 
(cap) of the 
device”) 
% not reported 
  
(“Press the 
device until it 
clicks”) 
% not reported 
 
(“Press the 
device steadily 
for 10 seconds 
(count to 10)”) 
22% of parents 
passed all recorded 
steps at first visit, 
68% at the 2nd visit 
and 94% at the 3ed 
visit 
At 2nd visit parental pass rate was 
higher for those whose child had 
venom allergy compared with 
food allergy  
 
99 parents receiving a trainer 
device had a better pass rate at 
2nd visit 
  
  
 
Segal et al., 2012 
Israel 
 
Before and after 
study with average 12 
months between 
instruction and re-
assessment  
 
Assessment by 
demonstration 
 
50% 
141  (129 parents 
of children with 
AIIs aged ≤12y 
and 12 aged >12y 
(total age range 
22m-23.4y) 
Not assessed  
 
 
Pre-instruction 
52% 
 
(“Removing the 
cap”) 
 
Pre-instruction 
32% 
 
(“Holding the 
device in first”) 
 
 
Pre-instruction 
34% 
 
(“Placing against 
upper outer 
thigh and 
pressing”) 
 
Not assessed 
 
 
Pre-instruction 
26% 
 
(“Holding in 
place for 10 
seconds”)  
 
6% were able to 
complete all steps 
at baseline (n=141) 
 
≤19% were able to 
complete all steps 
at first follow up 
(n=41) 
 
≤53% were able to 
completed all steps 
at second follow up 
(n=41) 
77% able to cite at least 2 
symptoms of systemic allergic 
reaction 
 
79% had a valid device 
 
100% trained in how to use 
device 
 
No significant difference 
between patients and parents 
demonstration technique 
Sicherer et al., 2012 
USA 
 
Longitudinal with 
before and after 
 
Assessment by 
demonstration 
immediate post-
education and 12-
months 
 
25% 
60 families 
(parent/caregiver
of a food allegic 
child prescribed 
AAI (aged 6 
months to 14y)  
 
33 completed 12-
month 
assessment 
Pre-education 
38% approx.* 
 
Immediate post-
education 100% 
 
12-months post-
education 70% 
 
 
 
(“Recognises 
device”) 
Pre-education 
78% approx.* 
 
Immediate post-
education 100% 
 
12-months post-
education 96% 
 
 
 
(“Removes cap”) 
Pre-education 
70% 
 
Immediate post-
education 100% 
 
12-months post-
education 96% 
 
 
 
(“Correct site”) 
Pre-education 
70% 
 
Immediate post-
education 100% 
 
12-months post-
education 94% 
 
 
 
(“Correct end”) 
Pre-education 
52% approx.* 
 
Immediate post-
education 95% 
approx.*  
 
12-months post-
education 94% 
approx.*  
 
(“Press to 
activate”) 
Pre-education 
28% approx.* 
 
Immediate post-
education 100% 
 
12-months post-
education 89% 
approx.*  
 
 
 (“Hold several 
seconds”) 
Pre-education 18%  
 
Immediate post-
education 95% 
 
12-months post-
education not 
reported 
 
88% pre-education, 98% post-
education and 100% 12-month 
post-education knew the AAI did 
not require refrigeration 
 
75%, 98% and 98% respectively 
knew AAI could be used through 
clothing 
Topal et al., 2012 
Turkey 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
64 (50 care givers 
of children with 
AAI and 14 
patients aged 
≥12y) 
72% approx.*  
 
(“Recognise the 
autoinjector”) 
70% approx.* 
 
(“Remove the 
grey safety cap”) 
98% approx.*  
 
(“Selecting the 
outer thigh”) 
93% approx.*  
 
(“Applying the 
black end to the 
thigh”) 
75% approx.* 
 
(“Pressing it until 
it clicks”) 
78% approx. * 
 
(“Holding it in 
place for at least 
10 s”) 
40%  
 
 
84% knew how to check the 
expiry date 
 
*Approximate values derived 
from figure  
 
History of severe anaphylaxis was 
associated with correct use of 
AAI administration (OR 28.3, 95% 
CI:2.50-321.38) 
 
No difference between parent 
and child competence in 
administering device 
Umasunthar et al., 
2015 
 
UK 
 
158 mothers of 
children (aged 0-
18y) with food 
allergy (145 
completed 6-
week assessment, 
110 completed 
Not assessed 6-weeks post-
training Anapen 
63%, EpiPen 71% 
 
12-months post-
training Anapen 
66%, EpiPen 90% 
6-weeks post-
training Anapen 
93%, EpiPen 93% 
 
12-months post-
training Anapen 
(See previous 
step) 
6-weeks post-
training Anapen 
100%, EpiPen 
82% 
 
12-months post-
training Anapen 
6-weeks post-
training Anapen 
86%, EpiPen 82% 
 
12-months post-
training Anapen 
88%, EpiPen 88% 
6-weeks post-
training Anapen 
42%, EpiPen 43% 
 
12-months post-
training Anapen 
55%, EpiPen 59% 
At 6-weeks post-training, 1% with 
Anapen and 5% EpiPen injected 
into the thumb, 56% Anapen and 
54% EpiPen massaged site after 
injection, 68% Anapen and 69% 
EpiPen called the emergency 
services 
  
  
 
RCT to receive EpiPen 
or Anapen and 
training 
 
Assessment by 
demonstration 6 
weeks and 1 year 
after initial training 
 
50% 
12-month 
assessment) 
 
 
 
(“Removal of all 
safety caps”) 
100%, EpiPen 
83% 
 
 
(“Placement of 
correct end of 
the device 
against the 
thigh”) 
100%, EpiPen 
98% 
 
(“Activation of 
device”) 
 
 
 
(“Holding the 
device in place 
for adrenaline 
delivery for ≥5s”) 
  
At 12-months, 0% with Anapen 
and 14% EpiPen injected into the 
thumb, 80% Anapen and 63% 
EpiPen massaged site after 
injection, 86% Anapen and 93% 
EpiPen called the emergency 
services 
 
After 12-months, 108 
participants were given an 
alternate device with no training. 
Participants receiving the Auvi-Q 
had highest administration 
success rate 93% vs 49% for all 
other devices 
 
  
  
  
 
 
Table 3. Health care professionals’ (HCPs) technique and skills administering an adrenaline auto-injector (Studies are presented in chronological order)  
 
Studies (country, 
design, method of 
observation, 
quality 
assessment) 
Study 
population 
% individuals correctly undertaking key steps of AAI administration 
 (wording used) 
100% correct Additional observations 
  Device 
Recognition 
Removal of 
safety cap 
Selection of 
appropriate 
injection site 
Application of 
correct end of 
AAI to thigh 
Administration 
of adrenaline 
Holding AAI in 
place  
  
Grouhi et al., 1999 
Canada 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
122 HCPs 
(physicians, 
medical students, 
pharmacist and 
nurses)  
 
Secondary care 
Not assessed 56% approx.*  
 
(“Pull out the 
grey safety cap”) 
44% approx.*  
 
(“Hold the device 
in the palm with 
the thumb 
covering the 
index finger and 
the black tip 
toward the small 
finger”) 
27% approx. * 
 
(“Place the black 
tip on the outer 
thigh. Push hard 
until you hear 
the trainer 
function. Hold in 
place for 10 
seconds”) 
See previous step See previous step 25% HCPs 19% had a training device with 
which to education patients 
(70% pharmacists) 
 
24% were aware of two 
available doses 
 
Majority of pharmacists 
performed well (80%) 
 
Primary care paediatricians 
(performed worst (6%) 
 
*Approximate values derived 
from figure 
Sicherer et al., 2000 
USA 
 
Cross-sectional  
 
Assessment by 
demonstration 
 
50% 
101 families of 
newly referred 
food allergic 
children (95 
parents and 6 
children, mean 
age 6.4y) & 36 
physicians 
 
Secondary care 
48% 
paediatricians 
51% paediatric 
residents 
approx.* 
 
(“Familiar with 
device” 
35% 
paediatricians 
51% paediatric 
residents 
approx.*  
 
 
(“Removes cap”) 
 
83% 
paediatricians 
90% paediatric 
residents 
approx.* 
 
 
(“Selects correct 
end”)  
88% 
paediatricians 
99% paediatric 
residents 
approx.* 
 
 
(“Selects correct 
injection site”) 
59% 
paediatricians 
81% paediatric 
residents 
approx.* 
 
 
(“Presses to 
activate”) 
48% 
paediatricians 
46% paediatric 
residents % 
approx.* 
 
 
(“Holds in place 
several seconds”)  
21% Paediatricians 
 
36% Resident 
Paediatricians 
 
17% HCPs reported training 
families to use AAI with trainer 
 
24% HCP provided written 
information on how to use 
device 
Onbasi et al., 2005 
Turkey 
 
Cross-sectional  
 
Assessment by 
questionnaire 
93 physicians 
 
Primary care 
Not reported Not reported Not reported Not reported Not reported Not reported 11% 24% knew the correct  dose, 
form and the route of 
administration  
 
 
  
  
 
 
25% 
Mehr, et al., 2007  
Australia 
Cross-sectional  
 
Assessment by 
demonstration 
25% 
100 physicians  
 
Tertiary care 
95%  
 
(“Recognized 
EpiPen”) 
96% 
 
(“Removed grey 
cap”) 
 
99% 
 
(“Select  outer 
thigh as body 
part”) 
84% 
 
(“Pressed  black 
end into the 
thigh”) 
79% 
 
(“Pressed to 
activate”) 
43% 
 
(“Held pen for 
>5s” ) 
2% Doctors 45% previously prescribed AAI 
 
51% provided patients with 
some education information on 
AAI administration technique 
and 7% provided a 
demonstration   
 
16% injected trainer into thumb 
reported 
Arga et al., 2011 
Turkey 
 
Before-after study  
 
Assessment by 
demonstration 
assessed 6 months 
after 
 
25% 
196 physicians 
 
Secondary care  
Not assessed  Pre-education 
89%   
Post-education 
97% 
 
(“Removed gray 
cap”) 
 
 
Pre-education 
85% 
Post-education 
99% 
 
(“Select outer 
thigh as body 
part”) 
 
Pre-education 
66% 
Post-education 
94% 
 
(“Placed black 
end into outer 
thigh”) 
Pre-education 
60% 
Post-education  
91% 
 
(“Pressed to 
activate”) 
Pre-education 
48% 
Post-education  
82% 
 
(“Held pen for > 
5s”) 
23% pre-education 
 
74% post-education  
 
41% knew indications of 
epinephrine auto-injector  
 
Self-injection into thumb (36% 
pre-education, 7% post-
education) 
Salter et al., 2014 
Australia 
 
Cross-sectional 
simulated patient- 
study 
 
Assessment by 
demonstration 
 
75% 
250 pharmacists 
 
Community care 
Not assessed 89%  
 
(“Remove safety 
cap” ) 
 
96% 
 
(“Place against 
thigh”) 
 
See next step 73% 
 
(“Push and 
inject”) 
 
21% 
 
(“Remove and 
massage 
injection site for 
10 seconds”) 
 
18% completed all 
steps (4 steps)  
 
65%  correctly 
completed 3 steps 
and  
Incorrect positioning of thumb 
observed in 12% 
 
Proper AAI was more likely if 
pharmacists asked patients if 
they had an anaphylaxis 
management plan (OR 16.1, 
95% CI:3.86-67.3), advised the 
patient to call an ambulance 
after administration (OR 4.00, 
95% CI:1.44-11.1) or explained 
the side effects of epinephrine 
(OR 4.45, 95% CI:1.48-13.4) 
Topal et al., 2014   
Turkey 
Cross-sectional  
 
Assessment by 
demonstration 
 
25% 
126 primary care 
physicians 
Primary care 
Not reported Not reported 34%  
(“Knew site for 
injection”) 
 
Not reported Not reported Not reported 34% knew how to 
administer device 
30% knew correct adrenaline  
dose 
  
  
 
 
 
Table 4. Participants’ AAI administration technique for studies including an instruction of AAI administration in design (studies are presented in chronological order) 
 Studies Type of instruction Method of observation Duration of retest Correct administration technique 
Al-Matar and Sussman, 2001 
 
Two minute instruction of correct 
administration technique was provided   
Demonstration using a trainer 
device 
Immediately following instruction Pre-instruction 13%  
 
Post-instruction 100% 
Kapoor et al., 2004 
 
A clinical nurse specialist educated 
participants on recognition and 
management of anaphylaxis. A 
specialist paediatric dietician gave 
advice regarding food allergen 
avoidance. 
Demonstration using a trainer 
device 
3 months Pre-instruction 50%  
 
Post-instruction 96% 
 
 
Huang, 2007 A physician observed participants 
demonstration technique before 
explaining any steps which needed to 
be corrected prior to demonstrating 
correct technique. Participants were 
then required to repeat the process 
until they completed all steps correctly. 
Observation by physician  No reported (first, second and 
third visits but duration between 
not provided) 
Pre-instruction (first visit) 22% 
 
Post-instruction (second visit) 68% 
 
Post-instruction (third visit) 94% 
Arga et al., 2011 
 
One-to-one practical session including 
visual and written prospectus on how to 
use AAI 
Demonstration using a trainer 
device 
6 months Pre-instruction 23%  
 
Post-instruction 74%  
 
Segal et al., 2012 
 
Participants received an individualized 
written emergency plan and 
instructions for the use of AAI plus 
training from one of three physycians 
Demonstration using a trainer 
device 
First follow-up visit after 0.04–
6.54 years (mean 1.28 years) 
 
Second follow-up visit after 1.02  
years (range 0.08–2.6 years) 
Pre-instructions 6%  
 
First follow up ≤19%  
 
Second follow up ≤53%  
Sicherer et al., 2012 
 
Education materials (written and video) 
on signs and symptoms of food allergy, 
labelling and when and how to use AAI 
Demonstration using a trainer 
device 
Immediate post-instruction and 
12 months 
Pre-instruction 18%  
 
Immediate post-instruction 95% 
 
12-months post-instruction not reported 
 
Umasunthar et al., 2015 
 
 
Standardised training including 
recognition and management of 
anaphylaxis by researcher who ensured 
participants were able to demonstrate 
correct technique before leaving the 
session plus written manufacturer 
device specific information 
Demonstration using a trainer 
device 
6 weeks and 12 months 6-weeks post-instruction Anapen 42%, 
EpiPen 43% 
 
12-months post-instruction Anapen 55%, 
EpiPen 59% 
 
 
